SEC Filing | Nektar Therapeutics

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wilson Mark Andrew

(Last)

(First)

(Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH, SUITE 100

(Street)

SAN FRANCISCO

94158

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/31/2020

3. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
SVP & General Counsel

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	53,947⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option	02/06/2017	02/05/2021	Common Stock	5,344	8.8	D
Stock Option	12/09/2018	12/08/2022	Common Stock	37,500	16.31	D
Stock Option	12/15/2019	12/14/2023	Common Stock	15,000	15.55	D
Stock Option	⁽²⁾	07/14/2024	Common Stock	10,000	15.45	D
Stock Option	⁽³⁾	12/12/2024	Common Stock	20,000	12.24	D
Stock Option	⁽⁴⁾	12/14/2025	Common Stock	110,000	56.9	D
Stock Option	⁽⁵⁾	12/14/2025	Common Stock	42,000	56.9	D
Stock Option	⁽⁶⁾	12/13/2026	Common Stock	10,225	36.51	D
Stock Option	⁽⁷⁾	12/11/2027	Common Stock	35,800	21.79	D
Stock Option	⁽⁸⁾	12/11/2027	Common Stock	11,600	21.79	D

Explanation of Responses:

1. This number includes 31,574 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. This number also includes 2,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c).

2. As of March 31, 2020, 9,166 shares subject to this stock option are vested and exercisable. The remaining 834 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until July 15, 2020 based on continued service.

3. As of March 31, 2020, 16,250 shares subject to this stock option are vested and exercisable. The remaining 3,750 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 13, 2020 based on continued service.

4. As of March 31, 2020, 61,875 shares subject to this stock option are vested and exercisable. The remaining 48,125 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 15, 2021 based on continued service.

5. As of March 31, 2020, 23,625 shares subject to this stock option are vested and exercisable. The remaining 18,375 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 15, 2021 based on continued service.

6. As of March 31, 2020, 3,195 shares subject to this stock option are vested and exercisable. The remaining 7,030 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 14, 2022 based on continued service.

7. As of March 31, 2020, 2,237 shares subject to this stock option are vested and exercisable. The remaining 33,563 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 12, 2023 based on continued service.

8. As of March 31, 2020, 725 shares subject to this stock option are vested and exercisable. The remaining 10,875 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 12, 2023 based on continued service.

Remarks:

	Mark Andrew Wilson	04/08/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.